Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
- Futures range-bound ahead of long weekend break
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Yen on intervention watch; Asia shares creep higher
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Alnylam Pharmaceuticals Discontinues Revusiran Development
October 5, 2016 4:30 PM EDTDecision Does Not Impact Patisiran or Any Other RNAi Therapeutic Program in Development
Company to Host Conference Call Today at 5:00 p.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend... More